In solvent-cast barrier films intended for temporary post-surgical adhesion control, PURASORB PLDL 7028 is dissolved at 8–12% w/v in dichloromethane, filtered through a 0.2 µm PTFE membrane, and doctored onto polyethylene terephthalate release liner with a 400–800 µm wet gap. The film is dried at 25–35 °C under nitrogen until residual dichloromethane falls below the ICH Q3C Class 2 limit of 600 ppm, then vacuum-dried at 40 °C for 24 h. Final thickness of 50–200 µm is achieved by solution solids and wet-gap adjustment rather than by post-casting orientation; the 70:30 L/DL-lactide backbone remains amorphous under these conditions, which avoids crystalline haze and anisotropic shrinkage during shelf storage. Terminal sterilization by ethylene oxide at 45 °C and 60% RH for 6 h is followed by aeration until residue limits in ISO 10993-7:2008 are met. Degradation is tracked in phosphate-buffered saline at pH 7.4 and 37 °C per ASTM F1635-16; because film thickness remains below 200 µm, acidic hydrolysis products diffuse away from the surface more readily than in thick injection-moulded rods, reducing internal autocatalysis and delaying central mass loss. Cytotoxicity is assessed per ISO 10993-5:2009 using L929 cells, implantation response per ISO 10993-6:2016, and sensitization per ISO 10993-10:2010. Converted sheets are packed as sterile absorbable barrier films under nitrogen, with lot-specific wet-gap adjustment required after each inherent viscosity measurement to compensate for low-IV batch variance.

What Limits Monofilament Draw Ratios in Low-IV 70:30 L/DL-Lactide Melt Spinning?

Monofilament suture extrusion from PURASORB PLDL 7028 is constrained by the gap between the temperature required for melt pumping and the onset of lactide reformation. Granules are dried at 80 °C under vacuum to residual moisture below 200 ppm by Karl Fischer titration per ISO 15512:2019 before feeding to an 18–25 mm single-screw extruder with 30:1 L/D and a 15 µm sintered-metal screen pack. Barrel zones are set at 150/165/175/180 °C from feed to metering, and melt temperature is maintained at 180–185 °C; above 190 °C, unreacted lactide is regenerated at a rate that produces die-lip deposits and filament diameter variation exceeding 10%. The amorphous low-IV melt has lower melt strength than semi-crystalline PLLA; a draw ratio above 4:1 between first and second godets induces draw resonance. A 1.0 mm spinneret, 20–25 °C water quench, and 1.5 m air gap are used, with first godet speed at 5 m/min and second godet speed at 20 m/min. Online laser-gauge tolerance is set at ±0.05 mm. Annealing at 70 °C for 12 h under nitrogen relaxes molecular orientation without inducing crystallinity; this improves knot security but limits straight-pull tensile strength compared with PLLA homopolymer. Knot-pull tensile strength and needle attachment are qualified under the current USP absorbable suture monograph and ISO 10993-5:2009. Final packaging is a nitrogen-flushed aluminium foil pouch with desiccant for monofilament absorbable suture in size 3-0 to 0. Because inherent viscosity is 0.28 dL/g, this grade is not suitable for high-strength orthopedic suture lines that normally require IV above 1.0 dL/g.

Because the 0.28 dL/g inherent viscosity grade dissolves more readily than higher-IV PLDL copolymers, microsphere encapsulation of heat-labile peptide and small-molecule APIs is run from a 10–20% w/v polymer solution in dichloromethane. The oil phase is emulsified into a continuous phase of 0.5–1.0% w/v poly(vinyl alcohol) in water using a rotor-stator homogenizer at 4,000–8,000 rpm for 2–5 min. The emulsion is transferred to an extraction bath of 0.1% w/v poly(vinyl alcohol) at 35–40 °C and stirred at 300 rpm for 4 h to extract solvent and harden the microspheres. Drug-to-polymer ratios from 1:20 to 1:5 are selected according to API potency and target release, with final drug loading typically 5–30% w/w. Particles are collected on a 20–100 µm sieve and lyophilized with 2–5% w/v mannitol; terminal moisture is specified below 1.0% by Karl Fischer. Residual dichloromethane is controlled to the ICH Q3C Class 2 limit of 600 ppm, and residual lactide is quantified by GC-FID per ISO 10993-13:2020. Aseptic processing is preferred over terminal gamma irradiation for this low-IV polyester; if gamma irradiation is unavoidable, post-irradiation inherent viscosity retention should be measured per ISO 1628-1:2021. In vitro release is characterized in pH 7.4 phosphate-buffered saline at 37 °C using USP Apparatus 4 or 2 with sinkers, and subvisible particulates are checked per USP <788>. The finished presentation is a lyophilized long-acting injectable suspension for intramuscular or subcutaneous use. The 30% DL-lactide fraction generates D-lactic acid on hydrolysis, which is cleared more slowly than L-lactate in humans; this is a recognized limitation in patients with compromised renal function.

When Injection Moulding Replaces Machining for Bioresorbable Fracture Pins

Net-shape injection moulding is used for small-diameter fracture fixation pins and interference screws because the low-IV PLDL 7028 melt fills thin-wall cavities at lower pressure than higher-IV grades, but the trade-off is a narrow processing window and notch sensitivity. Granules are dried at 80 °C under vacuum to below 150 ppm moisture; a moisture level above 250 ppm at melt temperatures above 170 °C causes hydrolysis-induced intrinsic viscosity loss greater than 15% as measured by ISO 1628-1:2021. An injection-moulding machine with a 15 mm screw, 20:1 L/D, and 250–500 kN clamp force is run with barrel zones 150/170/185/190 °C, nozzle temperature 190 °C, mould temperature 25–30 °C, injection speed 20–50 mm/s, and hold pressure 600–900 bar. Back pressure is kept at 10–20 bar and screw speed at 80–120 rpm to prevent shear heating beyond 195 °C, where lactide monomer reformation and brown discoloration appear in sprues. Since the amorphous matrix does not undergo crystallization shrinkage, warpage arises mainly from anisotropic flow orientation; post-moulding vacuum annealing at 70 °C for 4 h relaxes residual stress. Machining is restricted to light gate removal and thread chasing; aggressive turning or milling generates microcracks in this low-IV glass. Mechanical acceptance for the terminal pin or screw is evaluated per ASTM F2502-17, and in vitro degradation is monitored per ASTM F1635-16. At final inspection the pin or screw is packed in a double peel pouch under nitrogen, with outer diameter 5–9 mm. This application is limited to non-load-bearing or partially load-sharing indications; the 30% DL-lactide content and low IV do not provide the modulus or strength retention of drawn PLLA homopolymer used in high-load orthopedic hardware.

When a metallic coronary stent is spray-coated with a bioresorbable drug matrix, PURASORB PLDL 7028 is dissolved at 1–2% w/v in acetone or 60:40 v/v acetone–dichloromethane and sprayed through an ultrasonic nozzle operating at 20 kHz with solution flow rate 0.5–1.0 mL/min. The stent is rotated on a mandrel at 20–50 rpm while the nozzle traverses at 5–10 mm/s to deposit a coating of 5–15 µm. A drug-to-polymer ratio between 1:3 and 1:10 is used for antiproliferative APIs; the amorphous L/DL-lactide carrier provides a single-phase matrix that avoids crystalline drug release lag seen with PLLA homopolymer. Coated stents are vacuum-dried at 50 °C for 12 h and crimped onto delivery balloons at 40–60 °C; coating defects such as webbing and bridging are inspected by stereomicroscopy, and coating adhesion is tested under simulated deployment in 37 °C water. Residual solvent is controlled per ICH Q3C, and degradation products are characterized per ISO 10993-13:2020. Cytotoxicity and implantation assessments follow ISO 10993-5:2009 and ISO 10993-6:2016. The finished device configuration is a drug-eluting coronary stent system with a bioresorbable PLDL coating that degrades to lactic acid at vessel healing time scales; the D-lactate fraction from the DL-lactide segments slows local clearance relative to a pure L-lactide polymer.

Nonwoven conduits for peripheral nerve and dermal repair are electrospun from PURASORB PLDL 7028 dissolved at 10–15% w/v in 1,1,1,3,3,3-hexafluoroisopropanol or at 20–25% w/v in a 70:30 v/v chloroform–N,N-dimethylformamide mixture. A 21 G blunt-tipped needle, flow rate of 1–3 mL/h, applied voltage of 15–25 kV, and rotating drum collector at 300–500 rpm produce random nonwoven mats with fibre diameters of 300–1,200 nm; aligned fibres require collector surface speed of 1,000–2,000 rpm. The deposited mat is vacuum-dried at 40 °C for 24 h to remove residual solvent, and solvent extractables are verified by headspace gas chromatography per ISO 10993-18:2020. Ethylene oxide sterilization at 45 °C and 60% RH is preferred over gamma irradiation because the low-IV polyester is susceptible to radiation-induced chain scission; gamma processing at 25 kGy is not recommended without post-irradiation molecular weight confirmation. Published single-grade data for this specific PLDL 7028 electrospinning configuration is limited; the stated window is drawn from comparable amorphous PLDL solutions and must be verified against actual batch inherent viscosity and residual monomer. Final converted forms include tubular scaffolds with inner diameter 1–5 mm and wall thickness 200–500 µm, fabricated under ISO 13485:2016 quality controls. Because nonwoven electrospun PLDL has lower suture retention and burst strength than textile-reinforced grafts, the device is limited to soft-tissue regeneration where the scaffold is not primarily load-bearing. Cytotoxicity, sensitization, and implantation are assessed per ISO 10993-5:2009, ISO 10993-10:2010, and ISO 10993-6:2016.